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Gene expression profiles may clarify our understanding 
of the pathophysiology of disease, and by redefining 
pathways of inflammation may offer new alternatives for 
treatment of chronic diseases such as the spondylo-
arthropathies (SpA). If the expression profiles are specific 
for the disease or for a particular subgroup of patients, 
the data may generate biomarkers to classify the disease 
and define the stage of the inflammatory process. 
Genome-wide RNA expression analysis will thus lead to 
new insights in the pathogenesis of heterogeneous 
diseases such as SpA. These studies are expensive and 
powerful statistical approaches are necessary for 
achieving reproducible results. The potential gains, 
however, are of great clinical importance. Attention 
should be given to the selection of patients, to the state of 
the inflammatory process and to the possible effect of 
current therapy in the enhancing or silencing of this 
process.
As far as we know, only two studies have used whole 
genome expression profiles in blood from SpA patients 
and controls. Both studies follow a similar protocol; the 
study published in the previous issue of Arthritis 
Research and Therapy used an Affymetrix microarray 
system [1], and an Australian study published online in 
Annals of the Rheumatic Diseases used an Illumina Chip 
[2]. Both studies use a primary set and a validation set. 
Both studies also use peripheral blood, and obviously the 
pathogenesis of joints may be slightly different when the 
organ of disease is targeted. The approach, however, is 
valid.
The study described by Sharma and colleagues showed 
several interesting associations of axial SpA with the 
innate immune system – like the NOD-like receptor 
family member inflammasome component NLRP2, 
secre  tory leukocyte peptidase inhibitor I, and secreted 
protein acidic, cysteine-rich (also known as osteonectin) – 
and with inflammation markers (IL-1 receptors) and 
markers of bone remodeling (Kringle containing trans-
membrane protein 1 (KREMEN1)) [1]. Limitations of this 
study are the patient selection, which was based on 
uveitis, and that neither joint assessment nor radio-
graphic data were included to confirm the diagnosis of 
ankylosing spondylitis (AS). The more correct diag  nosis 
of axial SpA was therefore used. Unfortunately this 
patient selection limits the extrapolation of these data to 
AS or SpA.
Another important issue is the high number of females 
in the control group (80% in the combined sets) com-
pared with the SpA subjects (28%). It is not yet known 
whether gender differences may have influenced the 
mRNA expression profiles, and moreover whether this 
difference was taken into account with the linear models. 
More important is the racial difference between index 
cases (22% Asian) and controls (92% Caucasian, 8% non-
Caucasian) because up to 25% of the gene expression can 
be attributed to these racial differences [3]. This was not 
corrected in the linear models and might account for 
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The results of this study in SpA patients by Sharma and 
colleagues, although interesting, should therefore await 
validation with a similar group of selected patients. Some 
of these transcripts are related to genes previously 
described to be associated with AS (such as the IL-1 
family, and triggering receptor expressed on myeloid 
cells-like 1) but others (such as secretory leukocyte 
peptidase inhibitor I and secreted protein acidic, cysteine-
rich) are new. Secretory leukocyte peptidase inhibitor I, 
which downregulates TNF, could be an interesting target 
for future studies. Secreted protein acidic, cysteine-rich – 
associated with scleroderma – suggests an association 
with dysregulation of the fibrous tissue that might also be 
involved in the pathogenesis of AS. The most promising 
aspects for future research derive from the markers of 
bone remodeling – such as KREMEN1, which might 
influence the wnt-signaling pathway. These markers can 
give direction towards further larger studies with a 
proper definition of patients and follow up unraveling the 
intriguing balance between inflammation and ossification 
in the pathogenesis of AS.
The classification, genetic susceptibility, pathology, and 
response to treatment of spondyloarthritis have been 
evaluated into five interrelated subsets – namely, AS, 
psoriatic arthritis, reactive arthritis, arthritis associated 
with inflammatory bowel disease, and undifferentiated 
spondyloarthropathy – and have been reviewed, as have 
the classification criteria so far used [4]. The data 
presented by Sharma and colleagues in the previous issue 
of the journal and the previously quoted Australian study 
support that SpA as well as other autoimmune diseases 
will be better characterised at the level of gene 
expression. It is to be hoped that the understanding of 
the different pathways to inflammation will facilitate the 
assessment of disease activity and will improve targeting 
of therapies [5].
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